Hatchtech Pty Ltd has enrolled the first subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo.
This Phase 2b trial will evaluate the efficacy, safety and tolerability of two dose levels of a single application of DeOvo. It will use approximately 132 healthy subjects with head lice infestation, two years of age and older in two study centers in the United States.
Hatchtech’s proprietary agent, DeOvo, is a topical formulation of a known metalloprotease inhibitor, which targets certain proteases that are key to biological processes involved in insect hatch and survival.
Hatchtech Chairman Paul Kelly, PhD commented: “This is a big milestone for Hatchtech. DeOvo is a next generation head lice treatment therapy that targets all life cycle stages of the parasite with a single 10 minute application.”
“We have previously demonstrated that this agent effectively treats eggs and crawling lice in a small number of infested adults. Now we are assessing the compound in a larger clinical trial including adult and pediatric subjects.”
Release Date: May 2, 2011
Source: Hatchtech Pty Ltd
